Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay.

Jang, Woo Dae; Jeon, Sangeun; Kim, Seungtaek; Lee, Sang Yup

Jang, Woo Dae; Jeon, Sangeun; Kim, Seungtaek; Lee, Sang Yup.

Afiliação

Jang WD; Metabolic and Biomolecular Engineering National Research Laboratory, Department of Chemical and Biomolecular Engineering (BK21 four), KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea.
Jeon S; Systems Metabolic Engineering and Systems Healthcare Cross-Generation Collaborative Laboratory, KAIST, Daejeon 34141, Republic of Korea.
Kim S; Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam 13488, Republic of Korea.
Lee SY; Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam 13488, Republic of Korea; seungtaek.kim@ip-korea.org leesy@kaist.ac.kr.

Proc Natl Acad Sci U S A ; 118(30)2021 07 27.

Article em En | MEDLINE | ID: mdl-34234012

Assuntos

Antivirais/uso terapêutico; Tratamento Farmacológico da COVID-19; Reposicionamento de Medicamentos; Monofosfato de Adenosina/análogos & derivados; Monofosfato de Adenosina/uso terapêutico; Alanina/análogos & derivados; Alanina/uso terapêutico; Animais; Chlorocebus aethiops; Avaliação Pré-Clínica de Medicamentos; Sinergismo Farmacológico; Humanos; Interface Usuário-Computador; Células Vero

Palavras-chave

SARS-CoV-2; cell-based assay; docking-based virtual screening; drug combinations; drug repurposing

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Reposicionamento de Medicamentos / Tratamento Farmacológico da COVID-19 Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google